company background image
ELDN logo

Eledon Pharmaceuticals NasdaqCM:ELDN Stock Report

Last Price

US$4.27

Market Cap

US$255.1m

7D

-5.1%

1Y

141.9%

Updated

24 Dec, 2024

Data

Company Financials +

Eledon Pharmaceuticals, Inc.

NasdaqCM:ELDN Stock Report

Market Cap: US$255.1m

ELDN Stock Overview

Operates as a clinical stage biotechnology company. More details

ELDN fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Risk Analysis

Makes less than USD$1m in revenue ($0)

Earnings are forecast to decline by an average of 33% per year for the next 3 years

Shareholders have been substantially diluted in the past year

Volatile share price over the past 3 months compared to the US market

+ 1 more risk

My Notes

Capture your thoughts, links and company narrative

Eledon Pharmaceuticals, Inc. Competitors

Renovaro

NasdaqCM:RENB

US$163.5m

Lexicon Pharmaceuticals

NasdaqGS:LXRX

US$273.9m

Benitec Biopharma

NasdaqCM:BNTC

US$268.8m

Larimar Therapeutics

NasdaqGM:LRMR

US$241.2m

Price History & Performance

Summary of share price highs, lows and changes for Eledon Pharmaceuticals
Historical stock prices
Current Share PriceUS$4.27
52 Week HighUS$5.54
52 Week LowUS$1.52
Beta0.76
1 Month Change6.48%
3 Month Change71.49%
1 Year Change141.93%
3 Year Change-3.39%
5 Year Change-59.10%
Change since IPO-96.28%

Recent News & Updates

Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart

Oct 29

Recent updates

Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart

Oct 29

We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Mar 22
We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

Dec 05
Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

Aug 10
Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Apr 27
We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Situation

Jan 05
Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Situation

Eledon adds 10% as FDA clears clinical trial for kidney disease candidate

Sep 06

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Invest In Growth?

Aug 31
Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Invest In Growth?

Eledon gets FDA nod to start trial of organ rejection preventing therapy

Aug 01

Eledon begins dosing in early-stage study of tegoprubart in kidney transplant patients

Jul 18

Eledon gives update on development strategy for AT-1501 in renal transplantation

Apr 26

Eledon Pharmaceuticals (NASDAQ:ELDN) Is In A Good Position To Deliver On Growth Plans

Apr 14
Eledon Pharmaceuticals (NASDAQ:ELDN) Is In A Good Position To Deliver On Growth Plans

What Type Of Shareholders Make Up Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) Share Registry?

Feb 21
What Type Of Shareholders Make Up Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) Share Registry?

Here's Why We're Not Too Worried About Novus Therapeutics' (NASDAQ:NVUS) Cash Burn Situation

Dec 30
Here's Why We're Not Too Worried About Novus Therapeutics' (NASDAQ:NVUS) Cash Burn Situation

Novus Therapeutics (NVUS) Investor Presentation - Slideshow

Dec 18

Novus Therapeutics EPS misses by $3.76

Nov 16

Enrollment underway in Novus Therapeutics' mid-stage AT-1501 trial in neuromuscular disease

Nov 02

Shareholder Returns

ELDNUS BiotechsUS Market
7D-5.1%-3.3%-0.4%
1Y141.9%-2.7%24.8%

Return vs Industry: ELDN exceeded the US Biotechs industry which returned -1.9% over the past year.

Return vs Market: ELDN exceeded the US Market which returned 23.9% over the past year.

Price Volatility

Is ELDN's price volatile compared to industry and market?
ELDN volatility
ELDN Average Weekly Movement11.5%
Biotechs Industry Average Movement10.7%
Market Average Movement6.3%
10% most volatile stocks in US Market17.0%
10% least volatile stocks in US Market3.1%

Stable Share Price: ELDN's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: ELDN's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a20DA Groseledon.com

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential.

Eledon Pharmaceuticals, Inc. Fundamentals Summary

How do Eledon Pharmaceuticals's earnings and revenue compare to its market cap?
ELDN fundamental statistics
Market capUS$255.09m
Earnings (TTM)-US$24.55m
Revenue (TTM)n/a

0.0x

P/S Ratio

-10.4x

P/E Ratio

Is ELDN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ELDN income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$24.55m
Earnings-US$24.55m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.41
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did ELDN perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 06:21
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Eledon Pharmaceuticals, Inc. is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Edward WooAscendiant Capital Markets LLC
Alethia YoungCantor Fitzgerald & Co.
Pete StavropoulosCantor Fitzgerald & Co.